ストックスクリーナーアプリを入手
0.5286
0.67%
0.0035
プレマーケット:
.53
0.0014
+0.26%
前日終値:
$0.5251
開ける：
$0.52
24時間の取引高:
352.35K
Relative Volume:
0.02
時価総額：
$21.48M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+3.65%
1か月 パフォーマンス:
-13.34%
6か月 パフォーマンス:
-67.37%
1年 パフォーマンス:
-90.21%
1日の値動き範囲:
$0.5136
$0.5415
1週間の範囲:
$0.501
$0.5415
52週間の値動き範囲:
$0.461
$5.267
Scienture Holdings Inc Stock (SCNX) Company Profile
SCNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.5286 | 21.34M | 0 | 0 | 0 | 0.00 |
|
HITI
High Tide Inc
|
2.68 | 234.33M | 376.07M | -22.41M | 18.73M | -0.298 |
|
PETS
Petmed Express Inc
|
3.37 | 76.29M | 270.52M | -6.08M | 17.42M | -0.2944 |
|
RDGT
Ridgetech Inc
|
2.83 | 51.02M | 119.97M | -1.45M | 632.50K | -0.9847 |
|
WGRX
Wellgistics Health Inc
|
0.4052 | 42.96M | 28.99M | -39.20M | -3.34M | 0.00 |
|
POM
Pomdoctor Ltd Adr
|
0.3376 | 39.12M | 0 | 0 | 0 | 0.00 |
Scienture Holdings Inc (SCNX) 最新ニュース
Why Scienture Holdings Inc. stock is trending among retail tradersMean Reversion Trades & Explosive Growth Opportunities - ulpravda.ru
Scienture Holdings Inc. (SCNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
MSN Money - MSN
Will Scienture Holdings Inc stock beat EPS estimates2025 Pullback Review & Weekly Return Optimization Alerts - moha.gov.vn
Scienture Holdings, Inc.Common Stock (Nasdaq:SCNX) Stock Quote - FinancialContent
Scienture Holdings, Inc. (SCNX) - Zacks Investment Research
Scienture Prepares Launch Of REZENOPY, Its Highest-Strength Naloxone Nasal Spray - Nasdaq
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA - The Globe and Mail
Scienture to launch high-strength naloxone nasal spray in Q2 2026 - Investing.com Nigeria
Is Scienture Holdings Inc stock near bottom after declineJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - moha.gov.vn
Scienture (SCNX) Advances with REZENOPY Nasal Spray Launch - GuruFocus
Scienture to launch high-strength naloxone nasal spray in Q2 2026 By Investing.com - Investing.com South Africa
Scienture provides update on the commercial launch of Rezenopy - marketscreener.com
Scienture Provides Update On The Commercial Launch Of Rezenopy - TradingView — Track All Markets
New 10 mg overdose nasal spray set to reach U.S. market in 2026 - Stock Titan
Is Scienture Holdings Inc. stock a top momentum playPortfolio Performance Summary & Low Drawdown Investment Strategies - Улправда
Will Scienture Holdings Inc. (4E4) stock announce a stock split2025 Retail Activity & Precise Swing Trade Alerts - Улправда
How Scienture Holdings Inc. stock trades during market volatility2025 Technical Overview & Precise Swing Trade Alerts - Улправда
Is Scienture Holdings Inc. (4E4) stock included in top ETFs2025 Winners & Losers & Free High Return Stock Watch Alerts - DonanımHaber
How Scienture Holdings Inc. stock reacts to inflationary pressuresWeekly Trade Review & Risk Controlled Swing Alerts - DonanımHaber
Is Scienture Holdings Inc. stock a good choice for value investorsWeekly Trade Report & Free Weekly Watchlist of Top Performers - DonanımHaber
Is Scienture Holdings Inc. stock positioned for digital transformationTrade Exit Report & Weekly Top Performers Watchlists - DonanımHaber
What analyst consensus implies for Scienture Holdings Inc. (4E4) stockShort Setup & Reliable Breakout Stock Forecasts - DonanımHaber
Movement Recap: Is Scienture Holdings Inc 4E4 stock included in top ETFsJuly 2025 PostEarnings & Low Risk High Reward Ideas - moha.gov.vn
Is Scienture Holdings Inc 4E4 stock included in top ETFsJuly 2025 PostEarnings & Low Risk High Reward Ideas - moha.gov.vn
Scienture, BlinkRx announce strategic collaboration to expand access to Arbli - Yahoo Finance
Why Is Scienture Stock Gaining Today? - Benzinga
Scienture and BlinkRx partner to expand access to liquid losartan By Investing.com - Investing.com Australia
SCNX FinancialsIncome Statement - Quiver Quantitative
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - The Manila Times
Scienture and BlinkRx partner to expand access to liquid losartan - Investing.com India
Scienture (NASDAQ: SCNX) taps BlinkRx to launch Arbli, first ready-to-use losartan oral suspension in Q1 2026 - Stock Titan
A significant driver of top-line growth: Scienture Holdings Inc (SCNX) - Setenews
Scienture Holdings, Inc. Cash Flow – HAM:4E4 - TradingView
Can Scienture Holdings Inc. (4E4) stock beat analyst consensusTrade Signal Summary & Consistent Return Strategy Ideas - Newser
Head to Head Analysis: Summit Therapeutics (NASDAQ:SMMT) and Scienture (NASDAQ:SCNX) - Defense World
Scienture Holdings Inc (SCNX) 財務データ
Scienture Holdings Inc (SCNX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
6.39%
2.86%
大文字化:
|
ボリューム (24 時間):